TransMedics Group, Inc. Common Stock
TMDX
$92.21
+0.91%
TransMedics Group, Inc. is a commercial-stage medical technology company transforming organ transplant therapy for patients with end-stage organ failure, built around its proprietary Organ Care System (OCS) — a portable perfusion, optimization, and monitoring platform that replicates near-physiologic conditions to preserve and transport donor hearts, lungs, and livers outside the body, displacing traditional cold-storage methods. The company is best understood as a vertically integrated transplant logistics platform rather than a pure device vendor: it pairs its OCS hardware with a national organ transport service (revenue split roughly 56% product / 44% service in the latest quarter), giving it a defensible, capital-intensive moat that few medtech peers can replicate. The current investor debate centers on whether TransMedics can sustain hyper-growth as it scales into kidneys and European markets while absorbing heavy investment in aircraft, logistics, and R&D — a tension crystallized by a blowout Q3 2026 print (revenue +41% YoY) that nonetheless met a skeptical market reaction amid margin compression and a sharp year-to-date drawdown. Sentiment is further complicated by a violent post-earnings rally in early November that reversed months of underperformance, leaving bulls pointing to a durable multi-organ network and bears questioning the durability of growth and profitability.…
TMDX
TransMedics Group, Inc. Common Stock
$92.21
Related headlines
Investment Opinion: Should I buy TMDX Today?
Rating: Hold with a constructive bias. The core thesis is that TransMedics is a genuinely differentiated, vertically integrated transplant logistics platform growing revenue 41.15% YoY ($203.0M in Q3 2026) and trading at 6.83x PS — the bottom of its own 14.3x–25.9x historical band — but the stock has already re-rated 28% in a single session to $91.38, just 3.7% below its $94.77 52-week high, leaving little margin of safety until the next print confirms margin stabilization. The analyst tape supports this stance: five of six covering analysts are Buy/Outperform (Canaccord, Needham, TD Cowen, Piper Sandler, Evercore) with two Neutrals (UBS, JP Morgan) and zero Sells, and the tight EPS estimate cluster ($3.944–$4.399, an 11.5% spread) signals high conviction in the near-term earnings trajectory even though every ratings action in the dataset is a reiteration rather than an upgrade.
Supporting evidence is strong on growth and balance sheet, weaker on profitability quality. Revenue rose sequentially every quarter of 2026 ($173.9M → $189.9M → $203.0M) with both product ($113.4M) and service ($89.6M) scaling together; the $511.4M cash pile against a $4.1B market cap and a 7.14 current ratio fund the aircraft, logistics, and R&D buildout with essentially zero financing risk; free cash flow turned positive at $27.6M in Q3 (TTM $44.7M) after a negative $12.1M in Q1; and ROE of 40.2% with a 58.45% gross margin demonstrates real pricing power. Against that, gross margin has eroded from 61.4% in Q1 2025 to 58.45% in Q3 2026, net margin fell to 8.4% from 16.9% a year earlier, and diluted EPS of $0.46 trails basic EPS of $0.49 on 40.8M diluted versus 34.7M basic shares. The 6.83x PS is a modest 15–40% premium to the 4–6x typical of mature device peers, justified by 41% growth versus mid-single-digit sector growth, but the 27.7x EV/EBITDA and 21.4x PCF sit at the high end of the sector.
The biggest risks that could invalidate the thesis are (1) gross margin sliding further into the mid-50s as the service mix grows past 44% of revenue, (2) growth decelerating below 40% and triggering multiple compression from an already event-sensitive 58.76% max-drawdown profile, and (3) execution risk in the kidney and European rollouts that the two Neutral banks are explicitly waiting on. This Hold would upgrade to Buy on a pullback toward the $66–$69 support shelf or on a Q4 print showing gross margin troughing above 58% with revenue growth still above 40%; it would downgrade to Sell if gross margin breaks below 56% or growth decelerates below 30% without a credible margin-recovery path. Verdict: fairly valued to modestly undervalued relative to its own history, but fully valued relative to near-term fundamentals after the 28% gap — a stock to accumulate on weakness, not chase at the high.
Sign up to view all
TMDX 12-Month Price Forecast
The forward view is genuinely balanced: TransMedics has the growth (41.15% YoY), the balance sheet ($511.4M cash, 7.14 current ratio), and the valuation reset (6.83x PS at the bottom of its own band) that historically mark attractive entries in high-growth medtech, and the analyst consensus is firmly constructive with no Sells. But the stock has already captured much of that re-rating in a single 28% earnings gap and now sits 3.7% below its 52-week high, while the margin trend — gross margin down 295bps from Q1 2025 and net margin halved to 8.4% — is the one data series that has not yet stabilized. The base case (50%) is consolidation between $85 and $100 as growth moderates toward the low-30s and margins hold in the high-50s, with a 25% bull case to $105–$120 on kidney and European traction and a 25% bear case back to $66–$75 if margins break. I would upgrade to bullish on a Q4 print showing gross margin troughing above 58% with growth still above 40%, or on a pullback toward the $66–$69 support shelf that restores a margin of safety; I would downgrade to bearish if gross margin breaks below 56% or growth decelerates below 30%.
Wall Street consensus
Six analysts cover TMDX, and the institutional ratings tape shows a firmly constructive but not euphoric stance: the distribution skews toward Buy/Outperform (Canaccord Genuity Buy, Needham Buy, TD Cowen Buy, Piper Sandler Overweight, Evercore ISI Outperform) against two Neutral ratings (UBS and JP Morgan), with no Sell ratings — a roughly 5-to-2 bullish tilt. The consensus EPS estimate of $4.145 (range $3.944 to $4.399) and average revenue estimate of $1.15 billion (range $1.107 billion to $1.204 billion) imply the Street expects continued strong growth into the forward period, and the tight clustering of EPS estimates (a spread of only about 11.5% between low and high) signals relatively high conviction in the near-term earnings trajectory. Notably, the ratings actions in the data are all reiterations rather than upgrades or downgrades, suggesting analysts are holding their positions while waiting for confirmation from the kidney and European expansion rollouts. The target range is not explicitly provided in the dataset, so a precise implied upside cannot be calculated; however, the consensus revenue estimate of $1.15 billion against a $4.14 billion market cap implies a forward PS of roughly 3.6x, which — combined with the forward PE implied by the $4.145 EPS estimate — suggests the Street's models embed substantial multiple compression offset by earnings growth. The absence of any Sell ratings and the clustering of estimates around the mean indicate moderate-to-high conviction, but the presence of two Neutrals from major banks (UBS, JP Morgan) and the all-reiteration pattern suggest limited near-term catalyst-driven upside until the next earnings print validates the margin and growth trajectory. Investors should treat the consensus as cautiously bullish, with the key swing factor being whether TransMedics can demonstrate that its 40%+ growth is sustainable alongside stabilizing margins.
Bulls vs Bears: TMDX Investment Factors
The bull case currently has the stronger evidence: 41% revenue growth with sequential acceleration, a $511 million cash cushion, positive free cash flow, and a valuation sitting at the bottom of its own multi-year band (6.83x PS versus 14.3x–25.9x historically) collectively outweigh the margin-compression and dilution concerns. The bear case is real but largely about trajectory rather than solvency — gross margin eroding from 61.4% to 58.45% and diluted EPS trailing basic EPS by $0.03 are quality-of-earnings issues, not existential ones. The single most important tension is whether TransMedics can sustain 40%+ growth while stabilizing margins as the service/logistics mix grows; if margins keep sliding toward the mid-50s even as revenue compounds, the market's willingness to pay a premium multiple will erode further, but if margins trough and re-expand on operating leverage, the compressed multiple becomes the entry point. The recent 28% earnings gap and proximity to the $94.77 high mean the near-term setup is momentum-driven and fragile, so the thesis hinges on the next print validating both growth durability and margin stabilization.
Bullish
- Revenue re-accelerating above 40%: Q3 2026 revenue hit $203.0 million, up 41.15% YoY from $143.8 million, and rose sequentially every quarter of 2026 ($173.9M → $189.9M → $203.0M). This is steady sequential expansion, not a one-off spike, and both product ($113.4M) and service ($89.6M) segments are scaling together.
- Fortress balance sheet, self-funded growth: Cash of $511.4 million against a $4.1 billion market cap and a current ratio of 7.14 means the aircraft, logistics, and R&D buildout can be funded internally with essentially zero financing risk. Free cash flow turned positive at $27.6 million in Q3 (TTM FCF $44.7 million) after a negative $12.1 million in Q1.
- Valuation near multi-year lows: The PS ratio of 6.83x sits far below the 14.3x seen as recently as Q3 2026 and 25.9x at year-end 2025, and the trailing PE of 21.7x is at the bottom of a 39.5x–118x range across 2026 quarters. The multiple compression reflects both the 25.5% YTD decline and earnings catching up, a combination that historically marked attractive entries in high-growth medtech.
- Analyst consensus firmly constructive: Five of six covering analysts rate the stock Buy/Outperform (Canaccord, Needham, TD Cowen, Piper Sandler, Evercore) with only two Neutrals (UBS, JP Morgan) and zero Sells. The tight EPS estimate clustering (range $3.944–$4.399, an 11.5% spread) signals high conviction in the near-term earnings trajectory.
Bearish
- Gross margin compression trend: Gross margin has drifted from 61.4% in Q1 2025 to 59.6% in Q2 2026 and 58.45% in Q3 2026 as the lower-margin service/logistics mix grows. Net margin fell to 8.4% in Q3 2026 from 16.9% in Q3 2025, showing profitability is being diluted even as revenue grows.
- Dilution drag on per-share earnings: Diluted shares of 40.8 million versus 34.7 million basic produced diluted EPS of $0.46 against basic EPS of $0.49 in Q3 2026. This ~17.6% share-count gap means per-share economics lag the headline net income growth, a recurring drag as the company funds expansion.
- Stock pressing 52-week high after 28% gap: The stock jumped from $68.98 to $88.24 in a single session on the Q3 print and now trades at $91.38, roughly 97% of its 52-week range and just 3.7% below the $94.77 high. This leaves an unfilled gap and a support vacuum beneath the price, raising retest risk with a thin margin of safety for new entries.
- Severe volatility and drawdown history: The 58.76% maximum drawdown over the trailing period and a 28% single-day move underscore a high-beta, event-sensitive profile. The stock is still down 20.9% over one year and 25.5% YTD despite the recent rally, and relative strength versus the S&P is -33.2 points over 12 months.
TMDX Technical Analysis
TMDX is in a recovery phase within a longer-term downtrend: the stock is down 20.9% over the trailing year and 25.5% year-to-date, yet the current price of $91.38 sits at roughly 97% of its 52-week range (the 180-day window shows a low near $65.99 on 2026-10-30 and a high of $94.77 on 2026-08-21), placing it just below prior highs. This positioning signals strong short-term momentum but also meaningful overextension risk, since the stock has retraced nearly the entire year's decline in a matter of weeks. The 58.76% maximum drawdown over the period underscores how violently this name can swing, and the fact that it is now pressing against the upper boundary of its range means the margin of safety for new entries is thin. Recent momentum is decisively positive and accelerating: the stock is up 21.0% over the past month versus a 2.26% decline in the S&P 500 (a 23.3-point relative-strength spread), and up 3.16% over three months against a 2.83% SPY decline. The most striking feature is the single-session gap from $68.98 on 2026-11-05 to $88.24 on 2026-11-06 — a roughly 28% jump coinciding with the Q3 earnings release — which explains the divergence between the weak 1-year trend (-20.9%) and the explosive 1-month move (+21.0%). This kind of event-driven gap often marks a trend reversal rather than a temporary pullback, but it also leaves an unfilled gap and a vacuum of support beneath the new price level, raising the odds of a retest. Key technical levels are now well defined: support sits at the $66-$68 shelf (the October consolidation zone and 52-week low area), with secondary support at the pre-earnings $68.98 close, while resistance is the $94.77 52-week high, just 3.7% above the current $91.38. A clean breakout above $94.77 would confirm the reversal and likely trigger momentum-chasing flows, whereas a failure and breakdown back below $80 would signal the earnings gap was a false breakout and re-open the door to the $66 floor. With no beta provided, volatility must be inferred from the 58.76% max drawdown and the 28% single-day move, both of which imply a high-beta, event-sensitive profile that warrants smaller position sizing and wider stops than a typical large-cap medtech name.
Beta
—
—
Max Drawdown
-58.8%
Largest decline past year
52-Week Range
—
Price range past year
Annual Return
-19.8%
Cumulative gain past year
| Period | TMDX Return | S&P 500 |
|---|---|---|
| 1m | +30.3% | -3.0% |
| 3m | +1.7% | -3.6% |
| 6m | +35.6% | -0.2% |
| 1y | -19.8% | +10.1% |
| ytd | -24.8% | +8.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMDX Fundamental Analysis
Revenue growth remains robust and re-accelerating: Q3 2026 revenue reached $203.0 million, up 41.15% year-over-year from $143.8 million in Q3 2025, and up sequentially from $189.9 million in Q2 and $173.9 million in Q1 2026. The multi-quarter trajectory shows steady sequential expansion ($173.9M → $189.9M → $203.0M) with YoY growth holding above 40%, and the segment mix — $113.4 million product versus $89.6 million service — confirms that the higher-margin OCS hardware and the recurring logistics service are both scaling in tandem. This is the profile of a company still early in its penetration curve rather than one hitting a growth wall, which is the core of the bull case; however, the deceleration from the prior year's growth rates and the market's muted initial reaction to the beat suggest investors are already discounting a slowdown into 2027. Profitability is solid but showing signs of margin compression: Q3 2026 net income was $17.07 million (an 8.4% net margin) on gross profit of $118.66 million, a 58.45% gross margin that has drifted down from 61.4% in Q1 2025 and 59.6% in Q2 2026 as the lower-margin service/logistics mix grows. Operating income of $28.14 million (13.9% operating margin) was pressured by rising R&D ($29.18 million) and SG&A ($61.33 million), and the diluted EPS of $0.46 came in below the $0.49 basic figure due to a large diluted share count of 40.8 million versus 34.7 million basic — a meaningful dilution drag. The company is clearly profitable and cash-generative, but the trend of expanding opex and a heavier service mix means margin expansion is not assured, which is precisely the debate the bears are pressing. The balance sheet is a fortress: cash at the end of Q3 2026 stood at $511.4 million against a debt-to-equity ratio of 0.99 and a current ratio of 7.14, giving the company ample liquidity to fund its aircraft, logistics, and R&D buildout internally. Free cash flow turned positive at $27.6 million in Q3 (TTM FCF of $44.7 million) after a negative $12.1 million in Q1 driven by $36.7 million of capex, and operating cash flow of $36.0 million comfortably covered the $8.4 million quarterly capex. ROE of 40.2% is exceptional, though it is flattered by a relatively small equity base and the Q4 2025 tax-benefit distortion; the more telling metric is the $511 million cash pile relative to a $4.1 billion market cap, which provides a substantial cushion and reduces financing risk to near zero.
Quarterly Revenue
$203005000.0B
2026-09
Revenue YoY Growth
+41.1%
YoY Comparison
Gross Margin
58.5%
Latest Quarter
Free Cash Flow
$44696000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMDX Overvalued?
Because TransMedics is profitable (Q3 2026 net income of $17.07 million; TTM EPS of $0.046), the PE ratio is the appropriate primary metric, and here the trailing PE of 21.7x versus a forward PE of just 0.05x (reflecting the analyst consensus EPS estimate of $4.145 for the forward period) implies an extraordinary earnings inflection is expected — the market is pricing in a dramatic step-up in profitability that, if delivered, would make the stock look remarkably cheap on forward earnings. The trailing PE of 21.7x is also distorted by the Q4 2025 tax-benefit-inflated net income, so the more reliable read is the PS ratio of 6.83x and EV/EBITDA of 27.7x, both of which frame the stock as a premium growth multiple rather than a value name. Against a medical-devices industry where mature large-caps typically trade in the 15-25x PE and 4-6x PS range, TMDX's 6.83x PS represents a modest premium (roughly 15-40% above typical sector PS) that is more than justified by its 41% revenue growth — far above the mid-single-digit to low-double-digit growth of the device peer group. The EV/EBITDA of 27.7x and PCF of 21.4x sit at the higher end of the sector but are consistent with a company in a land-grab phase where cash flow is being reinvested into logistics infrastructure. Historically, TMDX has traded at far richer multiples: its PS ratio was 14.3x as recently as Q3 2026 and 25.9x at year-end 2025, and its PE ranged from 39.5x to 118x across 2026 quarters, meaning the current 6.83x PS and 21.7x PE sit near the bottom of the stock's own multi-year valuation band. This compression reflects both the sharp price decline (down 25.5% YTD) and the rapid earnings growth catching up to the multiple — a combination that historically has marked attractive entry points for high-growth medtech, though it also reflects the market's reduced willingness to pay a premium for the story amid margin-compression concerns.
PE
21.7x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 10x~164x
vs. Industry Avg
26.4x
Industry PE ~26.4x*
EV/EBITDA
27.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on margin erosion and dilution rather than liquidity. Gross margin has slid from 61.4% in Q1 2025 to 58.45% in Q3 2026 as the lower-margin service segment grows to 44% of revenue ($89.6M of $203.0M), and net margin fell to 8.4% in Q3 2026 from 16.9% a year earlier. Diluted shares of 40.8 million versus 34.7 million basic cut diluted EPS to $0.46 from a $0.49 basic figure, so per-share earnings lag headline net income. The offsetting strength is a $511.4 million cash pile, a 7.14 current ratio, and positive TTM free cash flow of $44.7 million, which means the risk is profitability quality, not balance-sheet stress. Market and competitive risks are dominated by valuation sensitivity and event-driven volatility. At 6.83x PS and 27.7x EV/EBITDA the stock still trades at a premium to the 4–6x PS typical of mature device peers, so any deceleration below 40% growth would likely trigger multiple compression; the 58.76% max drawdown and 28% single-day earnings gap confirm how violently the name reprices on news. Competitive disruption from cold-storage incumbents and execution risk in the kidney and European rollouts are the key operational threats, and the two Neutral ratings from UBS and JP Morgan plus an all-reiteration analyst tape suggest limited near-term catalyst support. The worst-case scenario is a chain in which the next earnings print shows growth decelerating below 40% while gross margin slips further into the mid-50s, prompting the Neutrals to turn negative and momentum flows to reverse the November gap. In that case the stock could retrace to the pre-earnings $68.98 close and the October consolidation shelf near $66, a decline of roughly -25% to -28% from the current $91.38, with the 52-week low of $65.99 representing the realistic floor and a full drawdown toward the 58.76% historical max implying far deeper losses if the growth story breaks.

